UY25659A1 - PROCEDURE FOR PREPARING COMPOUNDS OF 1- PIPERIDIN BENZOIMIDAZOLE 2- SUBSTITUTED AS AN OG1 RECEPTOR ANTAGONISTS - Google Patents
PROCEDURE FOR PREPARING COMPOUNDS OF 1- PIPERIDIN BENZOIMIDAZOLE 2- SUBSTITUTED AS AN OG1 RECEPTOR ANTAGONISTSInfo
- Publication number
- UY25659A1 UY25659A1 UY25659A UY25659A UY25659A1 UY 25659 A1 UY25659 A1 UY 25659A1 UY 25659 A UY25659 A UY 25659A UY 25659 A UY25659 A UY 25659A UY 25659 A1 UY25659 A1 UY 25659A1
- Authority
- UY
- Uruguay
- Prior art keywords
- useful
- substituted
- benzoimidazole
- piperidin
- procedure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un procedimiento para preparar nuevos compuestos de piperidin 4-il 1-sustituido benzoimidazol 2-sustituidos(FÓRMULA I), y sus sales farmacéuticamente aceptables, tienen acitividad antagonista del receptor ORL1, y son útiles como analgésico o similar en mamíferos Esta invención es útile en el tratamiento de enfermedades inflamatorias, hiperalgesia, trastornos de la alimentación, trastornos de la presión sanguínea arterial, trauma psíquico, Parkinson, Alzheimer, , epilepsia, convulsiones, agente neuroprotector o potenciador de analgésicos o útil para controlar el equinibio hídrico. Ejemplo: 2-Cloro-1-(1-(1-fenilcicloheptil)-4-piperidinil)-1-Hbenzoimidazol El compuesto donde R es cicloalquilo C3-C11 o cicloalquenilo, A es alquilo, arilo, h, halo, etc; Z1 a Z4 son hidrógenos o similarews; tienen actividad agonista del receptor ORL1 y es útil como analgésico o similar en mamíferosA method of preparing novel 4-substituted 1-substituted 1-benzoimidazole-piperidin compounds (FORMULA I), and their pharmaceutically acceptable salts, have ORL1 receptor antagonist activity, and are useful as a pain reliever or the like in mammals. This invention is useful in the treatment of inflammatory diseases, hyperalgesia, eating disorders, disorders of arterial blood pressure, psychic trauma, Parkinson's, Alzheimer's, epilepsy, seizures, neuroprotective agent or enhancer of analgesics or useful to control the water balance. Example: 2-Chloro-1- (1- (1-phenylcycloheptyl) -4-piperidinyl) -1-Hbenzoimidazol The compound where R is C3-C11 cycloalkyl or cycloalkenyl, A is alkyl, aryl, h, halo, etc; Z1 to Z4 are hydrogens or similarews; they have ORL1 receptor agonist activity and are useful as a pain reliever or the like in mammals
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IBPCT/IB98/01206 | 1998-08-06 | ||
| PCT/IB1999/001239 WO2000008013A2 (en) | 1998-08-06 | 1999-07-05 | 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25659A1 true UY25659A1 (en) | 2000-02-23 |
Family
ID=11004738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25659A UY25659A1 (en) | 1998-08-06 | 1999-08-13 | PROCEDURE FOR PREPARING COMPOUNDS OF 1- PIPERIDIN BENZOIMIDAZOLE 2- SUBSTITUTED AS AN OG1 RECEPTOR ANTAGONISTS |
Country Status (44)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6340681B1 (en) * | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
| SE9902987D0 (en) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| SE9903544D0 (en) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| EP1122257B1 (en) * | 2000-01-05 | 2005-10-12 | Pfizer Inc. | Benzimidazole compounds as ORL1-receptor agonists |
| GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| GB2359078A (en) * | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB0005642D0 (en) | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
| SE0003828D0 (en) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
| US6969712B2 (en) | 2000-11-15 | 2005-11-29 | Banyu Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| GB0104050D0 (en) | 2001-02-19 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
| SE0101322D0 (en) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| AU2002311833B2 (en) | 2001-04-18 | 2005-04-28 | Euro-Celtique S.A. | Spiropyrazole compounds |
| PT1598340E (en) | 2001-04-18 | 2009-04-13 | Euro Celtique Sa | 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain |
| SI1975164T1 (en) * | 2001-04-18 | 2010-05-31 | Euro Celtique Sa | Octahydrobenzimidazolone compounds as analgetics |
| JP4489354B2 (en) | 2001-04-18 | 2010-06-23 | ユーロ−セルティーク エス．エイ． | Spiroindene and spiroindane compounds |
| AU2002303406B2 (en) * | 2001-04-18 | 2006-03-30 | Euro-Celtique S.A. | Nociceptin analogs |
| CA2490386A1 (en) * | 2001-07-02 | 2003-01-16 | Omeros Corporation | Method for producing analgesia comprising administration of an opioid receptor agonist in rotation with an opioid receptor like-1 receptor agonist |
| US20030040479A1 (en) * | 2001-07-02 | 2003-02-27 | Omeros Corporation | Rotational intrathecal analgesia method and device |
| SE0102716D0 (en) * | 2001-08-14 | 2001-08-14 | Astrazeneca Ab | Novel compounds |
| SE0103818D0 (en) * | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| US7812035B2 (en) * | 2001-12-11 | 2010-10-12 | Sepracor Inc. | 4-substituted piperidines, and methods of use thereof |
| WO2003082333A1 (en) | 2002-03-29 | 2003-10-09 | Mitsubishi Pharma Corporation | Remedy for sleep disturbance |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0221829D0 (en) * | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| DE10252665A1 (en) | 2002-11-11 | 2004-06-03 | Grünenthal GmbH | 4-aminomethyl-1-aryl-cyclohexylamine derivatives |
| DE10252666A1 (en) | 2002-11-11 | 2004-08-05 | Grünenthal GmbH | N-piperidyl-cyclohexane derivatives |
| GB0315203D0 (en) * | 2003-06-28 | 2003-08-06 | Celltech R&D Ltd | Chemical compounds |
| SA04250305B1 (en) | 2003-09-25 | 2008-06-02 | سولفاي فارماسوتيكالز بي . في | The benzimidazolone derivatives cenzimidazolone and quinazolinone as agonists on the human ORL1 receptor. |
| GB0328243D0 (en) * | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
| US20050228023A1 (en) * | 2003-12-19 | 2005-10-13 | Sri International | Agonist and antagonist ligands of the nociceptin receptor |
| WO2006038738A1 (en) * | 2004-10-08 | 2006-04-13 | Takeda Pharmaceutical Company Limited | Receptor function regulating agent |
| EP1838306B1 (en) | 2005-01-11 | 2010-11-17 | NeuroSearch A/S | Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
| WO2008003667A2 (en) * | 2006-07-03 | 2008-01-10 | Neurosearch A/S | Combinations of monoamine reuptake inhibitors and potassium channel activators |
| JP5462633B2 (en) * | 2007-01-16 | 2014-04-02 | パーデュー、ファーマ、リミテッド、パートナーシップ | Heterocyclic substituted piperidine compounds and uses thereof |
| CA2697051C (en) * | 2007-08-31 | 2013-12-17 | Purdue Pharma L.P. | Substituted-quinoxaline-type piperidine compounds and the uses thereof |
| US8119661B2 (en) * | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| ES2393849T7 (en) | 2008-07-21 | 2015-01-28 | Purdue Pharma Lp | Bridged piperidine compounds, substituted quinoxaline type, and uses thereof |
| BR112013002879A2 (en) | 2010-08-05 | 2016-05-31 | Amgen Inc | benizmidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase |
| BR112014016548A8 (en) | 2012-01-06 | 2017-07-04 | Board Of Regents Of The Univ Of Oklahoma | sulfoxide based surfactants |
| EP2812372B1 (en) | 2012-02-09 | 2018-09-26 | Novus International Inc. | Heteroatom containing cyclic dimers |
| JO3300B1 (en) | 2012-06-06 | 2018-09-16 | Novartis Ag | Compounds and compositions for modulating egfr activity |
| BR112015000494A2 (en) | 2012-07-12 | 2017-06-27 | Novus Int Inc | matrix and layer compositions for the protection of biotives |
| US9085561B2 (en) * | 2012-07-30 | 2015-07-21 | Purdue Pharma L.P. | Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators |
| US9090618B2 (en) | 2012-12-27 | 2015-07-28 | Purdue Pharma L.P. | Substituted benzimidazole-type piperidine compounds and uses thereof |
| WO2014153529A1 (en) | 2013-03-22 | 2014-09-25 | The Scripps Research Institute | Substituted benzimidazoles as nociceptin receptor modulators |
| KR102663309B1 (en) | 2014-03-20 | 2024-05-03 | 카펠라 테라퓨틱스, 인크. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
| AU2016353076A1 (en) | 2015-11-12 | 2018-05-10 | Novus International Inc. | Sulfur-containing compounds as solvents |
| US10584306B2 (en) | 2017-08-11 | 2020-03-10 | Board Of Regents Of The University Of Oklahoma | Surfactant microemulsions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3318900A (en) * | 1964-05-06 | 1967-05-09 | Janssen Pharmaceutica Nv | Derivatives of benzimidazolinyl piperidine |
| JPS5297978A (en) * | 1976-06-02 | 1977-08-17 | Yoshitomi Pharmaceut Ind Ltd | Preparation of alicyclic derivatives |
| US5821219A (en) | 1995-08-11 | 1998-10-13 | Oregon Health Sciences University | Opioid antagonists and methods of their use |
| WO1997007208A1 (en) | 1995-08-15 | 1997-02-27 | Universite Libre De Bruxelles | Nucleic acid molecules encoding peptides having pronociceptive properties |
| US5866346A (en) | 1995-09-27 | 1999-02-02 | Indiana Unversity Foundation | Methods of using dynorphins as ligands for XOR1 receptor |
| DE69736776T2 (en) * | 1996-04-19 | 2007-01-18 | Neurosearch A/S | 1- (4-PIPERIDYL) -BENZIMIDAZOLE WITH NEUROTROPHIC ACTIVITY |
| EP0813065A3 (en) | 1996-06-13 | 1998-07-22 | F. Hoffmann-La Roche Ag | Modulation of LC132 (opioid-like) receptor function |
| EP0829481A1 (en) * | 1996-09-16 | 1998-03-18 | Pfizer Inc. | Morphinan hydroxamic acid compounds |
| US5718912A (en) * | 1996-10-28 | 1998-02-17 | Merck & Co., Inc. | Muscarine agonists |
| DE69826278T2 (en) | 1997-05-30 | 2005-11-10 | Banyu Pharmaceutical Co., Ltd. | 2-OXOIMIDAZOL DERIVATIVES |
| AU8334298A (en) | 1997-07-15 | 1999-02-10 | Novo Nordisk A/S | Nociceptin analogues |
| US5929035A (en) | 1998-04-14 | 1999-07-27 | Regents Of The University Of Michigan | Methods of treating intestinal disorders |
| ID29137A (en) | 1998-07-27 | 2001-08-02 | Schering Corp | HIGH AFINITY LIGANS FOR ORL-1 NOSISEPTIN RECEPTORS |
-
1999
- 1999-06-25 MA MA25646A patent/MA26659A1/en unknown
- 1999-06-28 TW TW088110899A patent/TW513424B/en not_active IP Right Cessation
- 1999-07-05 BR BR9912778-4A patent/BR9912778A/en not_active Application Discontinuation
- 1999-07-05 PT PT99926688T patent/PT1102762E/en unknown
- 1999-07-05 TN TNTNSN99142A patent/TNSN99142A1/en unknown
- 1999-07-05 CA CA002339621A patent/CA2339621C/en not_active Expired - Fee Related
- 1999-07-05 ID IDW20010284D patent/ID27212A/en unknown
- 1999-07-05 ES ES99926688T patent/ES2185357T3/en not_active Expired - Lifetime
- 1999-07-05 EA EA200100104A patent/EA200100104A1/en unknown
- 1999-07-05 DE DE69903953T patent/DE69903953T2/en not_active Expired - Fee Related
- 1999-07-05 EP EP99926688A patent/EP1102762B1/en not_active Expired - Lifetime
- 1999-07-05 WO PCT/IB1999/001239 patent/WO2000008013A2/en not_active Application Discontinuation
- 1999-07-05 HU HU0103567A patent/HUP0103567A3/en unknown
- 1999-07-05 AP APAP/P/2001/002063A patent/AP2001002063A0/en unknown
- 1999-07-05 CZ CZ2001397A patent/CZ2001397A3/en unknown
- 1999-07-05 PL PL99346211A patent/PL346211A1/en not_active Application Discontinuation
- 1999-07-05 EE EEP200100075A patent/EE200100075A/en unknown
- 1999-07-05 HN HN1999000105A patent/HN1999000105A/en unknown
- 1999-07-05 SI SI9930151T patent/SI1102762T1/en unknown
- 1999-07-05 SK SK160-2001A patent/SK1602001A3/en unknown
- 1999-07-05 IL IL14102999A patent/IL141029A0/en unknown
- 1999-07-05 OA OA1200100031A patent/OA11590A/en unknown
- 1999-07-05 AU AU43859/99A patent/AU749166B2/en not_active Ceased
- 1999-07-05 YU YU8201A patent/YU8201A/en unknown
- 1999-07-05 TR TR2001/00403T patent/TR200100403T2/en unknown
- 1999-07-05 NZ NZ509299A patent/NZ509299A/en not_active Application Discontinuation
- 1999-07-05 AT AT99926688T patent/ATE227716T1/en not_active IP Right Cessation
- 1999-07-05 JP JP2000563646A patent/JP3367945B2/en not_active Expired - Fee Related
- 1999-07-05 GE GEAP19995740A patent/GEP20033000B/en unknown
- 1999-07-05 CN CN99810857A patent/CN1317968A/en active Pending
- 1999-07-05 DK DK99926688T patent/DK1102762T3/en active
- 1999-07-06 AR ARP990103264A patent/AR018686A1/en active IP Right Grant
- 1999-07-15 PE PE1999000717A patent/PE20000868A1/en not_active Application Discontinuation
- 1999-07-16 PA PA19998477701A patent/PA8477701A1/en unknown
- 1999-07-16 SV SV1999000099A patent/SV1999000099A/en not_active Application Discontinuation
- 1999-08-05 US US09/369,208 patent/US6172067B1/en not_active Expired - Fee Related
- 1999-08-06 GT GT199900125A patent/GT199900125A/en unknown
- 1999-08-13 UY UY25659A patent/UY25659A1/en not_active Application Discontinuation
-
2001
- 2001-01-16 IS IS5812A patent/IS5812A/en unknown
- 2001-02-01 ZA ZA200100900A patent/ZA200100900B/en unknown
- 2001-02-02 HR HR970081A patent/HRP20010089B1/en not_active IP Right Cessation
- 2001-02-05 NO NO20010603A patent/NO20010603L/en not_active Application Discontinuation
- 2001-03-01 BG BG105301A patent/BG105301A/en unknown
-
2002
- 2002-02-26 HK HK02101444.8A patent/HK1040188A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25659A1 (en) | PROCEDURE FOR PREPARING COMPOUNDS OF 1- PIPERIDIN BENZOIMIDAZOLE 2- SUBSTITUTED AS AN OG1 RECEPTOR ANTAGONISTS | |
| IL245146A0 (en) | Inhibitors of human phosphatidyl-inositol 3-kinase delta | |
| TW200716523A (en) | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | |
| MY139296A (en) | CRYSTALLINE ß2 ADRENERGIC RECEPTOR AGONIST | |
| MXPA05012678A (en) | CRYSTALLINE FORM OF beta2. | |
| MXPA05000715A (en) | Novel inhibitors of kinases. | |
| DK1438052T3 (en) | Quinazolin-4-ones of inhibitors such as human phosphatidylinositol 3-kinase delta | |
| BR0311326A (en) | 4- (substituted cycloalkylmethyl) imidazol-2-thione, 4- (substituted cycloalkenylmethyl) imidazole-2-thione, 4- (substituted cycloalkylmethyl) imidazole-2-ones and 4- (substituted cycloalkenylmethyl) imidazole-2-ones ) and related compounds | |
| DE60236078D1 (en) | IMPROVED TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TREATMENT OF PARKINSON DISEASE | |
| MY142431A (en) | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | |
| ATE403426T1 (en) | OPIOID RECEPTOR ACTIVE 4-(3-HYDROXYPHENYL) OR 4-(3-ALKOXYPHENYL)-1,2,4-TRIAZOLE COMPOUNDS | |
| US20180021303A1 (en) | Bkca channel activator for treating muscular disorder | |
| WO2009096701A3 (en) | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | |
| NO20071403L (en) | 4- (phenylmethyl and substituted phenylmethyl) imidazole-2-tions acting as specific alpha2 adrenergic agonists | |
| MXPA06003374A (en) | Benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors. | |
| GB2352972A (en) | Use of dexmedetomidine for icu sedation | |
| ATE382618T1 (en) | R-(-)-1-[2-(7-CHLOROBENZO-[B-THIOPHEN-3-YL-METHOXY)-2-(2,4-DICHLORPHENYL)ETHYL -1H-IMIDAZOLE | |
| TW200519102A (en) | Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | |
| MD4802C1 (en) | Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines | |
| WO1998032429A3 (en) | P2 receptor agonists, antagonists and modulators of endogenous atp release for the treatment of skin conditions and the improvement of wound healing | |
| Mundell | New therapeutic agents in veterinary dermatology | |
| NO20080285L (en) | Alpha (aryl or heteroarylmethyl) -beta-piperidinopropionic acid compounds as ORL-1 receptor antagonist | |
| EP1333828B1 (en) | Prevention of development of dyskinesias | |
| WO2010002209A3 (en) | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same | |
| JP2007527868A (en) | 5-Chloro-1- (2,6-dichloro-4-trifluoromethylphenyl) -4- (4,5-dicyano-1H-imidazol-2-yl)-in systemic control of mite infestation on animals Use of 3-methyl-1H-pyrazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20110728 |